Federal Register #2026-11935

NIH/NIA Seeks Partners for Novel IMiD Analogs with Anti-Inflammatory Properties

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), is seeking research co-development partners and licensees for novel immunomodulatory imide drug (IMiD) analogs. - Government Buyer: - National Institutes of Health (NIH) - National Institute on Aging (NIA) - OEMs and Vendors: - No specific commercial OEMs or vendors are named; the compounds are developed by NIA researchers - Products/Technologies Requested: - Novel IMiD analogs, including 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones and related phthalimides - No part numbers or specific quantities provided - Intended Applications: - Systemic degenerative and neurodegenerative disorders - Inflammatory and autoimmune diseases - Viral infections and cancer - Unique/Notable Requirements: - Compounds feature improved chemical stability, enhanced water solubility, potent anti-inflammatory activity, and reduced teratogenicity - Opportunity is for research co-development and licensing, not direct product procurement - No administrative or procedural contract details are included

Description

This notice announces an amended meeting of the Center for Scientific Review Special Emphasis Panel on Circuit Disorders, Plasticity and Neuronal Injury. The meeting date has been changed to end on June 22, 2026. The meeting is closed to the public and is related to the National Institutes of Health under the Department of Health and Human Services.

View original listing